Taken together, these results suggest that PBMCs from LC patients may be a tool to study the activation of immune pathways with novel drugs such as DDR inhibitors that are under clinical investigation for LC; also, these results may be of interest if correlated with the presence of germline DDR gene alterations as potential novel biomarkers. Here, DDR1 is linked to laryngotracheoesophageal cleft.